add site
services
publishers
database
health videos
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN
| advertise add site services publishers database health videos
| | about toolbar stats live show health store more stuff JOIN/LOGIN |
| Health World US Business Political Technology Entertainment Sports Popular |
Novartis Looks at Combination Pills to Fix Hypertension FranchiseBNET - - Nov 24, 2009 Novartis' second-in-command BP medicine is Exforge, a single-pill combination of its AT-II receptor antagonist Diovan and the CCB amlodipine. ... Research and Markets: Hypertension: A Global Survey of the Latest Treatments ...Earthtimes (press release) - Nov 20, 2009 Angiotension II Receptor Antagonists. Estimated percentage of patients prescribed the following angiotensin II receptor antagonists, for the treatment of ... Committee For Medicinal Products For Human Use Summary Of Positive Opinion For ...PharmaLive.com (press release) - Nov 20, 2009 ... an Angiotensin II-antagonists medicinal product (ATC Code: C09CA07) that displaces angiotensin II from its binding site at the AT1 receptor subtype, ... Effects of High-Dose Versus Low-Dose Losartan on Clinical Outcomes in Patients ...Cardiosource - Nov 18, 2009 Methods: Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL) was a double-blind randomized trial, which included 3846 HF ... Sales of Therapies to Treat Diabetic Retinopathy, Diabetic Neuropathy and ...PR Newswire (press release) - Nov 18, 2009 The report also finds that the imminent loss of patent protection for many of the widely prescribed drugs in the angiotensin II receptor antagonists ... HEAAL: High-dose losartan associated with reduced mortality, HF hospitalizationEndocrine Today - Nov 17, 2009 An up-titration of the angiotensin receptor blocker in patients with HFbestowed incremental clinical benefit. A higher dose of the angiotensin ... HEAAL: High-dose trumps low-dose ARB for heart failure in the ACE-inhibitor ...TheHeart.Org - - Nov 17, 2009 Publication of the group's report, from the Heart Failure End Point Evaluation of Angiotensin II Antagonist Losartan (HEAAL) study, was timed to coincide ... Rise of the Machines — Left Ventricular Assist Devices as Permanent Therapy ...New England Journal of Medicine (subscription) - - Nov 17, 2009 High rates of inotropic support (79%) and low rates of use of angiotensin-converting–enzyme inhibitors (33%), angiotensin II–receptor antagonists (8%), ... Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL ...Cardiosource - - Nov 17, 2009 This study does not provide insight into high-dose angiotensin-receptor blocker therapy among patients who tolerate ACE inhibitors. AHA: Tripling ARB Dose Improves HF OutcomesMedPage Today - - Nov 17, 2009 ORLANDO -- Maximizing the dose of the angiotensin receptor blocker losartan (Cozaar) for heart failure ... | How to call the show... 1) Make sure the show is live (see graphic above). 2) Dial 724-444-7444. 3) Enter Call ID# 27566 when prompted. 4) Follow the phone prompts to join the call. Would you like to be a special guest on the show? Send us an email which includes your contact information and the topic(s) that you would like to discuss. Listen to past shows featuring special guests...  Bernard von NotHaus (Liberty Dollar)Aubrey de Grey, PhDDr. Amanuel Sima, MDDr. Bard Levey, DDSNeal AdamsRobin Scovill (director)Richard Diaz (author)Dr. Kaayla T. Daniel, CCNChana de Wolf, (cryonics researcher)Dr. Mary Ruwart (author & scientist)Richard Diaz (author)Dr. Jason Helliwell, OB/GYN |
| ↑ top of page ↑ | about thumbshots |
